StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

Equities researchers at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays reduced their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Stock Up 1.1 %

NASDAQ CLLS opened at $1.88 on Thursday. Cellectis has a 1 year low of $1.70 and a 1 year high of $3.77. The stock has a market capitalization of $104.50 million, a PE ratio of -1.45 and a beta of 3.10. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The business’s 50-day moving average is $1.98 and its 200 day moving average is $2.22.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same quarter in the prior year, the business posted ($0.31) earnings per share. Sell-side analysts forecast that Cellectis will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. grew its stake in Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares during the period. XTX Topco Ltd purchased a new stake in shares of Cellectis in the 2nd quarter worth about $29,000. First Affirmative Financial Network purchased a new stake in shares of Cellectis in the 3rd quarter worth about $45,000. Finally, Long Focus Capital Management LLC increased its stake in shares of Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares in the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.